$90 Million to Bolster Clinical and Manufacturing Capabilities

Privately held Epicrispr Biotechnologies has raised $90 million in a Series C funding round led by Octagon Capital and Janus Henderson Investors. The funds will be used to advance the late-stage clinical development and expand the manufacturing capabilities for its lead candidate, EPI-321, for the treatment of facioscapulohumeral muscular dystrophy (FSHD). This follows a $55 million Series A round in 2022 and a $68 million Series B round in 2025, strengthening the company's financial foundation to support the patient tracking, process development, and regulatory activities required after entering clinical trials. However, this is an equity investment rather than a licensing agreement, so there will be no milestones or royalties.

Single-Dose Epigenetic Therapy Targeting DUX4

EPI-321, identified by its development code rather than a brand name or international nonproprietary name (INN), is a single-dose, intravenous therapy that delivers a non-integrating dCas-based gene editing system (GEMS) to muscle cells using an adeno-associated virus (AAV) vector. It works by re-methylating the D4Z4 region without cutting the DNA sequence, thereby suppressing the expression of DUX4, the pathogenic protein responsible for FSHD. While this approach reduces the risk of genomic damage associated with permanent gene editing, the AAV-related immune response, limitations on re-administration, and the efficiency of systemic muscle delivery need to be validated clinically. Therefore, the company's valuation depends more on the consistency between DUX4 biomarker changes and functional improvements than on the theoretical advantages of the platform.

Early Signals and Interpretational Challenges in Phase 1/2 Trials

The global, first-in-human Phase 1/2 trial (NCT06907875) is an open-label, dose-escalation study involving 12 adult patients with FSHD1, and the enrollment and dosing of the two dose cohorts were completed in July 2026. As of May 12, 2026, nine patients had been dosed, and the initial three patients who could be evaluated showed an increase in lean muscle volume on a 6-month MRI, with no serious adverse events reported. However, given the small sample size of three and the lack of a control group in this safety-focused trial, it is not yet possible to consider this as definitive evidence of disease-modifying efficacy. Additional safety, biomarker, and functional data will be presented at the World Muscle Society meeting in September 2026, which will serve as the basis for designing a pivotal trial.

Competing with Avidity in a $600 Million Market

The FSHD treatment market is estimated at approximately $600 million in 2025, combining the United States, EU4, the United Kingdom, and Japan. However, there are currently no disease-modifying therapies approved by the FDA, EMA, or PMDA. Losmapimod, a p38α/β inhibitor developed by Fulcrum Therapeutics (FULC), failed to meet the primary endpoint in the 48-week analysis of the Phase 3 REACH trial in September 2024, leading to the discontinuation of its development. The main competitor is delpacibart braxlosiran (del-brax, AOC 1020), a DUX4-targeted antibody-oligonucleotide conjugate developed by Avidity Biosciences, which is in late-stage clinical trials. EPI-321 received FDA orphan drug designation in November 2023 and has also secured fast-track and rare pediatric disease designations, but approval and priority review depend on the successful completion of future clinical and regulatory requirements.